Home
About
Overview
Sharing Data
ORCID
Help
History (11)
Reizis, Boris
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
See All 11 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
View in:
PubMed
subject areas
Carcinoma, Non-Small-Cell Lung
DNA Helicases
Humans
Kelch-Like ECH-Associated Protein 1
Lung Neoplasms
Mutation
NF-E2-Related Factor 2
Nuclear Proteins
Phosphatidylinositol 3-Kinases
Transcription Factors
authors with profiles
Marina Chiara Garassino
Christine Bestvina